Update of the STARS Study: Sarizotan Treatment of Apneas in Rett Syndrome скачать в хорошем качестве

Update of the STARS Study: Sarizotan Treatment of Apneas in Rett Syndrome

Stefan Weber, CEO of Newron Pharmaceuticals, provides an update on the “Sarizotan Treatment of Apneas in Rett Syndrome” (STARS) study, a potential pivotal clinical study performed in study centers in the US, Europe, Asia, and Australia to evaluate the efficacy, safety and tolerability of sarizotan in patients with Rett syndrome suffering from respiratory symptoms. Sarizotan is a highly selective compound for specific serotonin or dopamine receptors that modulates the activity of these neurotransmitters in the brain. Sarizotan could become the first drug approved for Rett syndrome, a debilitating genetic disorder with no specific treatment options. Sarizotan is targeting respiratory disturbances as primary efficacy outcome in an ongoing pivotal study. In preclinical evaluation studies, the full agonist at the serotonergic 5HT1A receptor has demonstrated dramatic improvement of respiration in a number of genetic mouse model of Rett.